Haematopoietic growth factors and their therapeutic use

Thrombosis and Haemostasis

Volumn 99, Issue 5, 2008, Pages 863-873

  Wadhwa, Meenu ^a   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Adverse; Biosimilars; Haematopoiesis; Second generation; Stem cells

Indexed keywords

ANCESTIM; ASBSEAMED; BINOCRIT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ELTROMBOPAG; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; MICERA; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 3; RECOMBINANT STEM CELL FACTOR; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; RETACRIT; SILAPO; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ALLERGY; ANEMIA; APLASIA; APLASTIC ANEMIA; BONE PAIN; CAPILLARY LEAK SYNDROME; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DISEASE ASSOCIATION; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; EDEMA; ERYTHRODERMA; FLUID RETENTION; HEART ATRIUM ARRHYTHMIA; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUNG EDEMA; MACROPHAGE; MONOCYTE; MYELODYSPLASIA; NEUTROPENIA; NONHUMAN; PAPILLEDEMA; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SIDE EFFECT; T LYMPHOCYTE; TACHYCARDIA; THROMBOCYTOPENIA; WEIGHT GAIN;

ANIMALS; BIOLOGICAL PRODUCTS; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-11; INTERLEUKIN-3; MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS; STEM CELL FACTOR; THROMBOPOIETIN;

EID: 43949135506     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-11-0703     Document Type: Review

References (129)

1. Nicola NA, et al. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 1983; 258: 9017-9023.
2. Welte K, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82: 1526-1530.
3. Nomura H, et al. Purification and characterization of human granulocyte colony-stimulating factor (G-CSF).EMBO J 1986; 5: 871-876.
4. Nagata S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986; 319: 415-418.
5. Souza LM, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61-65.
6. Nicola NA. Hemopoietic cell growth factors and their receptors. Annu Rev Biochem 1989; 58: 45-77.
7. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
8. Platzer E. Human hemopoietic growth factors. Eur J Haematol 1989; 42: 1-15.
9. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844-2853.
10. Rutella S, et al. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol 2004; 34: 1291-1302.
11. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28-35.
12. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992; 327: 99-106.
13. Ozer H, et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: 3558-3585.
14. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors 2005; 23: 33-41.
15. Heuser M, et al. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. Semin Hematol 2007; 44: 148-156.
16. Ottmann OG, et al. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol 2007; 44: 183-192.
17. Dührsen U, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081.
18. Möhle R, Kanz L. Hematopoietic growth factors for hematopoietic stem cell mobilization and expansion. Semin Hematol 2007; 44: 193-202.
19. Ings SJ, et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-525.
20. Oh-eda M, et al. O-Linked sugar chain of human granulocyte stimulating factor protects it against polymerisation and denaturation allowing it to retain its biological activity. J Biol Chem 1990; 265: 11432-11435.
21. Balaguer H, et al. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260-1261.
22. Tigue CC, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40: 185-192.
23. Graber SE, Krantz SB. Erythropoietin and the control of red cell production. Annu Rev Med 1978; 29: 51-66.
24. Lin FK, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580-7584.
25. Constantinescu SN, et al. The erythropoietin receptor: Structure, activation and intracellular signal transduction. Trends Endocrinol Metab 1999; 10: 18-23.
26. Takeuchi M, et al. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. J Biol Chem 1990; 265: 12127-12130.
27. Lukowsky WA, Painter RH. Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem 1972; 50: 909-917.
28. Eschbach JW, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
29. de Campos E, et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995; 13: 1623-1631.
30. Osterborg A, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87: 2675-2682.
31. Means RT Jr, et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 1989; 32: 638-642.
32. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 (Suppl 1): 3-10.
33. Elliott S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414-421.
34. Casadevall N, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475.
35. Metcalf D, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67: 37-45.
36. Ruef C, Coleman DL. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990; 12: 41-62.
37. Jones TC. The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med Oncol 1996; 13: 141-147.
38. Caux C, et al. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261.
39. Wong GG, et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985; 228: 810-815.
40. Lee F, et al. Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. Proc Natl Acad Sci USA 1985; 82: 4360-4364.
41. Gearing DP, et al. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J 1989; 8: 3667-3676.
42. Hayashida K, et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci USA 1990; 87: 9655-9659.
43. Gerhartz HH, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82: 2329-2339.
44. Mellstedt H, et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 1999; 6: 169-175.
45. Lieschke GJ, et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989; 110: 357-364.
46. Wadhwa M, et al. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 1996; 104: 351-358.
47. Wadhwa M, et al. Immunogenicity of granulocytemacrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999; 5: 1353-1361.
48. Huang E, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63: 225-233.
49. Williams DE, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-174.
50. Zsebo KM, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver - conditioned medium. Cell 1990; 63: 195-201.
51. Huang EJ, et al. Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. Mol Biol Cell 1992; 3: 349-362.
52. Arakawa T, et al. Glycosylated and unglycosylated recombinant-derived human stem cell factors are dimeric and have extensive regular secondary structure. J Biol Chem 1991; 266: 18942-18948.
53. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345-1364.
54. Glaspy JA, et al.Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 9: 2939-2951.
55. To LB, et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003; 31: 371-378.
56. Jensen BM, et al. Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. Inflamm Allergy Drug Targets 2007; 6: 57-62.
57. Paul SR, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87: 7512-7516.
58. Turner KJ, Clark SC. Interleukin-11; biological and clinical perspectives. In: Hematopoietic growth factors in clinical applications. Marcel Dekker 1995: 315-336.
59. Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994; 83: 2023-2030.
60. Paul SR, Schendel P. The cloning and biological characterization of recombinant human interleukin 11. Int J Cell Cloning 1992; 10: 135-143.
61. Quesniaux VF, et al. Interleukin-11 stimulates multiple phases of erythropoiesis in vitro. Blood 1992; 80: 1218-1223.
62. Gordon MS, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615-3624.
63. Kaye JA. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 1998; 16 (Suppl 2): 207-223.
64. Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339: 746-754.
65. de Sauvage FJ, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538.
66. Kaushansky K, et al.Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-571.
67. Lok S, et al.Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-58.
68. Broudy VC, et al. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89: 1896-1904.
69. Fielder PJ, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782-2788.
70. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134: 453-466.
71. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354: 2034-2045.
72. Yang M, et al. Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expression. Br J Haematol 2000; 111: 371-380.
73. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann NY Acad Sci 2005; 1044: 139-141.
74. Ivanovic Z, et al. A clinical-scale expansion of mobilized CD 34+ hematopoietic stem and progenitor cells by use of a new serum-free medium. Transfusion 2006; 46: 126-131.
75. Begley CG, Basser RL. Biologic and structural differences of thrombopoietic growth factors. Semin Hematol 2000; 37: 19-27.
76. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
77. Vadhan-Raj S, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126: 673-681.
78. Li J, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
79. Basser RL, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99: 2599-2602.
80. Ciurea SO, Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol 2007; 44: 166-182.
81. Bussel JB, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672-1681.
82. Bussel JB, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
83. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-4741.
84. Stasi R, et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008; 99: 4-13.
85. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229-1237.
86. Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991; 254: 529-533.
87. Clark-Lewis I, et al. Purification to apparent homogeneity of a factor stimulating the growth of multiple lineages of hemopoietic cells. J Biol Chem 1984; 259: 7488-7494.
88. Yang YC, et al. Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 1986; 47: 3-10.
89. Leary AG, et al. Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1987; 70: 1343-1348.
90. Kitamura T, et al. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 1991; 66: 1165-1174.
91. Miyajima A, et al. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood 1993; 82: 1960-1974.
92. Platzer E, et al. Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 1985; 162: 1788-1801.
93. Eder M, et al. IL-3 in the clinic. Stem Cells1997; 15: 327-333.
94. Ganser A, et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 1990; 76: 455-462.
95. Ganser A, et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666-676.
96. Kurzrock R. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. Clin Cancer Res 2005; 11: 1361-1367.
97. Tushinski RJ, et al. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 1982; 28: 71-81.
98. Stanley ER, et al. CSF-1 - a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 1983; 21: 151-159.
99. Ralph P, Sampson-Johannes A. Macrophage growth and stimulating factor, M-CSF. Prog Clin Biol Res 1990; 338: 43-63.
100. Kirma N, et al. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta 1 in inducing c-fms expression. Cancer Res 2007; 67: 1918-1926.
101. Sherr CJ. Colony-stimulating factor-1 receptor. Blood 1990; 75: 1-12.
102. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006; 18: 39-48.
103. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
104. Oppenheim JJ, Gery I. Interleukin 1 is more than an interleukin. Immunol Today 1982; 3: 113-119.
105. Bagby GC Jr. Interleukin-1 and hematopoiesis. Blood Rev 1989; 3: 152-161.
106. Smith KA. T-cell growth factor. Immunol Rev 1980; 51: 337-357.
107. Gearing A, et al. Human B cell proliferation is stimulated by interleukin 2. Immunol Lett 1985; 9 : 105-108.
108. Robb R. Interleukin-2: the molecule and its function. Immunol Today 1984; 5 : 203-209.
109. Trinchieri G, et al. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984; 160 : 1147-1169.
110. Callard RE. Immunoregulation by interleukin-4 in man. Br J Haematol 1991; 78: 293-299.
111. Yokota T, et al. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hemopoietic cells. Immunol Rev 1988; 102: 137-187.
112. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
113. Rennick D, et al.Interleukin-6 interacts with interleukin-4 and other hematopoietic growth factors to selectively enhance the growth of megakaryocytic, erythroid, myeloid, and multipotential progenitor cells. Blood 1989; 73: 1828-1835.
114. Clutterbuck E, et al. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol 1987; 17: 1743-1750.
115. Clutterbuck EJ, et al. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989; 73: 1504-1512.
116. Namen AE, et al. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988; 167: 988-1002.
117. Conlon PJ, et al. Murine thymocytes proliferate in direct response to interleukin-7. Blood 1989; 74: 1368-1373.
118. Yang YC, , et al. Expression cloning of cDNA encoding a novel human hematopoietic growth factor: human homologue of murine T-cell growth factor P40. Blood 1989; 74: 1880-1884.
119. Kobayashi M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF),a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
120. Lieberman MD, et al. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. J Surg Res 1991; 50: 410-415.
121. Carson WE, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395-1403.
122. Grabstein KH, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264: 965-968.
123. Goey H, et al. Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factorbeta 1. J Immunol 1989; 143: 877-880.
124. Rigby WF, et al. The effects of recombinant-DNA-derived interferons on the growth of myeloid progenitor cells. Blood 1985; 65: 858-861.
125. Naranda T, et al. Activation of erythropoietin receptor through a novel extracellular binding site. Endocrinology 2002; 143: 2293-2302.
126. Thorpe R, Wadhwa M. Protein therapeutics and their immunogenicity. Eur J Hosp Pharm Pract 2006; 12 : 17-18.
127. Wadhwa M, Thorpe R. Unwanted immunogenicity: Is it a problem for biosimilar products? BIOforum Europe 2006; 10 : 46-48.
128. Wadhwa M, Thorpe R. Unwanted immunogenicity: Implications for follow-on biologicals. Drug Inf J 2007; 41: 1-10.
129. Mellstedt H, et al. The challenge of biosimilars. Ann Oncol 2007; Epub ahead of print.